Projects per year
Abstract
Bronchiectasis is a heterogeneous disease with multiple aetiologies and diverse clinical features. There is a general consensus that optimal treatment requires precision medicine approaches focused on specific treatable disease characteristics, known as treatable traits. Identifying subtypes of conditions with distinct underlying biology (endotypes) depends on the identification of biomarkers that are associated with disease features, prognosis or treatment response and which can be applied in clinical practice. Bronchiectasis is a disease characterised by inflammation, infection, structural lung damage and impaired mucociliary clearance. Increasingly there are available methods to measure each of these components of the disease, revealing heterogeneous inflammatory profiles, microbiota, radiology and mucus and epithelial biology in patients with bronchiectasis. Using emerging biomarkers and omics technologies to guide treatment in bronchiectasis is a promising field of research. Here we review the most recent data on biomarkers in bronchiectasis.
Original language | English |
---|---|
Article number | 230234 |
Number of pages | 19 |
Journal | European Respiratory Review |
Volume | 33 |
Issue number | 173 |
DOIs | |
Publication status | Published - 3 Jul 2024 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Fingerprint
Dive into the research topics of 'Biomarkers in bronchiectasis'. Together they form a unique fingerprint.Projects
- 1 Active
-
Is Neutrophil Inflammatory Phenotype Regulated By Olfactomedin-4 In Bronchiectasis (Clinical Academic Fellowship)
Chalmers, J. (Investigator) & Shoemark, A. (Investigator)
1/04/22 → 31/03/25
Project: Research